Sucroferric oxyhydroxide

Velphoro® Doubles Percentage of Patients Reaching Target Serum Phosphorous Levels in New Study Published in Journal of Renal Nutrition

Retrieved on: 
Monday, January 28, 2019
Medicine, Clinical medicine, Medical specialties, Phosphate binders, RTT, Sucroferric oxyhydroxide, Hyperphosphatemia, Dialysis, Cardiovascular disease, Phosphorus, Calcium acetate/magnesium carbonate, Chronic kidney disease

High serum phosphorous levels, or hyperphospatemia, have previously been associated with increased cardiovascular disease and mortality.

Key Points: 
  • High serum phosphorous levels, or hyperphospatemia, have previously been associated with increased cardiovascular disease and mortality.
  • Oral phosphate binders, in combination with dialysis and dietary restriction, have been shown to effectively lower elevated phosphorus levels.
  • Sucroferric oxyhydroxide (Velphoro) is a non-calcium, chewable, iron-based phosphate binder indicated for the treatment of hyperphosphatemia in dialysis patients.
  • For more details of the study, read the manuscript online in the Journal of Renal Nutrition .